Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerOpenAI sign Language
VIPCreated with Sketch.

Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.

Markus Moehler,Hong Xiao,Steven I Blum,Elena Elimova,David Cella,Kohei Shitara,Jaffer A Ajani,Yelena Y Janjigian,Marcelo Garrido,Lin Shen,Kensei Yamaguchi,Tianshu Liu,Michael Schenker,Ruben Kowalyszyn,Arinilda Campos Bragagnoli,Ricardo Bruges,Vincenzo Montesarchio,Roberto Pazo-Cid,Shannon Hunter,Eric Davenport,Jinyi Wang,Kaoru Kondo,Mingshun Li,Lucjan Wyrwicz

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）

Cited 0|Views59
No score
Abstract
Compared with chemotherapy alone, first-line nivolumab plus chemotherapy showed stable or better on-treatment HRQoL in patients with advanced/metastatic non-HER2-positive GC/GEJC/EAC and also showed decreased risk of definitive HRQoL deterioration.
More
Translated text
Key words
chemotherapy versus chemotherapy,gastric/gastroesophageal junction cancer,nivolumab,gastric/gastroesophageal adenocarcinoma,health-related
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined